December 29, 2008 – When Zemiva, an imaging agent by Molecular Insight Pharmaceuticals Inc., is combined with the standard of care for the diagnostic evaluation of the chest pain patient, improved the detection of cardiac ischemia by more than 50 percent greater than the standard of care when compared to the standard of care alone.
